Navigation Links
Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy

s when a cancer is progressing, were similarly conclusive. While 62.5% of the patients treated with docetaxel exhibited an over 50% reduction in PSA, a reduction of only 11.1% was detected among those treated with vinorelbine. This is a clear indication that docetaxel restricts tumour growth.

Even the team working on the study were surprised at the scale of the reduction in PSA produced by docetaxel. Prof. Krainer explains: "We used a much lower dose than that used during the TAX 327 study, which was the first to demonstrate the efficacy of docetaxel in a phase III trial, and we also chose not to boost the efficacy of the chemotherapy drug with cortisone premedication. Nevertheless, we still achieved a similar effect on PSA." Prof. Krainer believes this effect could be due to the lower toxicity which was produced by using a lower dose and which helped improve the efficacy of the therapy regimen.

Cancer specialist Dr. William K. Oh from the Dana-Farber Cancer Institute at Harvard Medical School also highlights this finding in his editorial comment attached to the publication. In his opinion, the therapy regimen used in Vienna offers a good alternative for patients in whom steroids are contraindicated. He also points out that the study demonstrated a 28.6% reduction of PSA in patients who had stopped responding to docetaxel and were instead using vinorelbine as second line chemotherapy, indicating that this drug will continue to play an important role in cancer treatment.

SMALL STUDY ­ BIG ISSUE This open-label, randomized phase II trial involved a total of 40 chemotherapy-naïve patients with histologically proven androgen-independent prostate cancer. The patients were divided into two groups that were given 25mg/m2 weekly doses of docetaxel or vinorelbine. Referring to the scope of the trial, Prof. Krainer states: "Of course, smaller studies such as this phase II trial cannot produce definitive conclusions. These can only be generated by
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
5. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
6. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
7. Quest PharmaTechs Prostate Cancer Program Update
8. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
Post Your Comments:
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 3 CareFusion Corporation (NYSE: CFN ), a leading, ... the spinoff of Cardinal Health,s clinical and medical products businesses, ... host a conference call on Thurs., Nov. 5, 2009 at ... , The company is changing the date of its earnings ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer ... on Thursday, November 12, 2009, at 4:00 PM EST ... the first quarter ended September 30, 2009, and the ... , Corgenix invites all those interested in hearing management,s ...
Cached Medicine Technology:CareFusion Moves First Quarter Earnings Announcement to November 5 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... further evidence to suggest that an enzyme secreted by the ... for new drugs to combat the deadly infectious disease. ... G (PknG), as a promising drug target back in 2004. ... is the secret weapon that enables the TB bug, Mycobacterium ...
... More bicycle riding and other lifestyle changes are urgently needed ... health and could also threaten the economy, the World Health ... indirectly to about 77,000 deaths per year in the region, ... is on the health of the people. If the trend ...
... have announced the birth of the first baby to be produced ... then frozen and defrosted for later use. ,The ... or who cannot be administered drugs that help egg maturation in ... around one year old, was born in Canada after work at ...
... advocates called Monday for tougher regulations on tobacco, as ... ways of boosting global efforts to stop smoking. ... Health Organisation (WHO) aims to find ways of harmonising ... advertising and protection from second-hand smoke. ,Hatai ...
... sleeping under insecticide-treated bed nets might protect older children ... transmission originates from adults and children over five years ... and are more attractive to mosquitoes. ,Current ... children and pregnant women in order to achieve over ...
... recognizing familiar smells could be experiencing an early sign of ... ,Scientists already know that the first lesions of the ... of the brain that is home to olfactory senses. ... tested 589 people aged between 54 to 90, and asked ...
Cached Medicine News:Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:First Baby Born from Eggs Matured and Frozen in the Lab 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum ...
... donors on the PK7200 Automated Microplate System, ... attached to a gelatin particle for the ... of the CMV assay as compared to ... use of a gelatin particle as the ...
Medicine Products: